ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1423

Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting

Regan Arendse1, Proton Rahman2, Philip Baer3, Derek Haaland4, Dalton Sholter5, Odalis Asin-Milan6, Meagan Rachich7, Emmanouil Rampakakis8, A. Marilise Marrache9 and Allen J. Lehman10, 1Community Rheumatology Care, Saskatoon, Canada, 2Memorial University, St. John's, NL, Canada, 3Baer Weinberg MPC, Scarborough, ON, Canada, 4The Waterside Clinic, Oro Medonte, ON, Canada, 5University of Alberta, Edmonton, AB, Canada, 6Janssen Canada, Laval, QC, Canada, 7Janssen Inc., Guelph, ON, Canada, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 10Janssen Inc., Toronto, ON, Canada

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Biologicals, Cardiovascular, registry, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Golimumab (GLM), a tumor necrosis factor inhibitor (TNFi), has demonstrated efficacy and a favorable safety profile in inflammatory rheumatic diseases. Recent safety studies with Janus kinase inhibitors (JAKi) sparked new discussions in this therapeutic area, while real-world evidence for GLM continues to support its long-term safety profile1-4. This analysis aimed to describe the risk of major adverse cardiovascular events (MACE), malignancy, and mortality in a large observational cohort of patients (pts) with RA, PsA, or axSpA treated with subcutaneous (SC) GLM. Serious adverse events (SAEs) and serious infections (SIs) were also assessed.

Methods: Post-hoc analysis of the BioTRAC registry, a prospective, multicenter study that collected real-world clinical, laboratory, safety, and patient-reported data in RA, PsA, and axSpA patients treated with GLM, infliximab, or ustekinumab. In the current analysis, only pts treated with SC GLM were included, excluding one pt with prior JAKi treatment. The incidence rates (IR) per 100 patient years (PYs) of AEs of special interest (AEoSI; MACE [defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke], malignancies excluding non-melanoma skin cancer, all-cause death, SAEs, SIs), irrespective of causality to GLM, and time to onset were assessed in subgroups based on the following factors: < 65 vs. ≥65 years of age; sex; prior TNFi experience; smoking status; baseline (BL) use of methotrexate (MTX) and oral steroids. All analyses were stratified by indication.

Results: 1,231 pts were included, 529 with RA, 281 with PsA, and 421 with axSpA. Table 1 summarizes the BL prevalence of risk factors of interest. Over 1064 (RA), 539 (PsA), and 675 (axSpA) PYs, the IR for MACE were 1.1 (n=12), 0.0, and 0.0 events/100 PYs, respectively, while for malignancies the IRs were 1.4, 0.4, and 1.0/100 PYs. SAE incidence ranged from 7.6/100 PYs in PsA pts to 11.4 in RA pts and that of SIs from 1.3/100 PYs in PsA pts to 2.3 in RA pts. IRs for all-cause mortality were 0.7/100 PYs (n=7), 0.2 (n=1), and 0.3 (n=2) /100 PYs in RA, PsA, and axSpA, respectively. Table 2 summarizes the incidence of AEoSI by presence vs absence of risk factors; although numerical differences were observed (e.g. increased rate of malignancy, mortality, and SI in pts ≥65 vs. < 65 years of age), there were no new safety signal. Higher age was associated with shorter time to MACE in RA pts (Figure); no significant association was observed with sex, prior TNFi experience, smoking, and concomitant MTX or steroid use.

Conclusion: Treatment results with GLM in a real-world diverse population are consistent with the current safety profile. This was irrespective of the presence or absence of the examined risk factors for RA, PsA and axSpA. Higher age was associated with shorter time to MACE in RA pts. GLM remains a safe option for the treatment of rheumatic diseases even in the presence of risk factors.

References:
1. Rajpal A. FDA Update on Safety Issues in the Treatment of Rheumatic Disease. ACR Convergence 2021.
2. Rahman P et al. BMC Rheumatol. 2020 Sep 19;4:46
3. Rahman P et al. BMJ Open. 2020 Aug 13;10(8):e036245
4. Rahman P et al. BMC Rheumatol. 2020 Nov 15;4(1):56

Supporting image 1

Table 1. Baseline Risk Factors of Interest by Indication

Supporting image 2

Table 2. Summary of AEs of Special Interest During GLM Treatment by Risk Factor

Supporting image 3

Figure 1. Time to MACE During GLM Treatment by Age Group


Disclosures: R. Arendse, None; P. Rahman, Janssen, Novartis, AbbVie, Eli Lilly and Company, Pfizer; P. Baer, Eli Lilly, Pfizer, Novartis, AstraZeneca, GlaxoSmithKlein(GSK), AbbVie, Amgen, Organon, Janssen, Fresenius Kabi, Viatris, Teva, Gilead, Celltrion, Opticann, Innomar, McKesson, JAMP Pharma, Ontario Rheumatology Association, Journal of Rheumatology, Journal of the Canadian Rheumatology Association; D. Haaland, AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb(BMS), Eli Lilly, GlaxoSmithKlein(GSK), Janssen, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda, Merck/MSD, UCB, Celgene, Adiga Life-Sciences, Can-Fite Biopharma, Regeneron, Gilead; D. Sholter, Janssen, Eli Lilly, Novartis, AbbVie/Abbott; O. Asin-Milan, Janssen; M. Rachich, Janssen; E. Rampakakis, Janssen, JSS Medical Research; A. Marrache, Janssen Pharmaceutical Companies of Johnson & Johnson, Johnson & Johnson; A. Lehman, Janssen.

To cite this abstract in AMA style:

Arendse R, Rahman P, Baer P, Haaland D, Sholter D, Asin-Milan O, Rachich M, Rampakakis E, Marrache A, Lehman A. Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/long-term-treatment-with-golimumab-is-a-safe-treatment-option-regardless-of-risk-factors-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-axial-spondyloarthritis-results-from-a-real-wo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-treatment-with-golimumab-is-a-safe-treatment-option-regardless-of-risk-factors-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-axial-spondyloarthritis-results-from-a-real-wo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology